A PHASE 3, SINGLE-ARM, MULTICENTER, OPEN-LABEL EXTENSION OF STUDY ARGX-113-2007 TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD PH20 SC IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHY
- Registry ID
- ARGX-113-2011
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ARGENX BV
- Start date
- 2025-02-19
- Last update
- 2023-06-13
Conditions
- IDIOPATHIC INFLAMMATORY MYOPATHY
View on source registry